Literature DB >> 33039401

Autosomal Recessive Bestrophinopathy: Clinical Features, Natural History, and Genetic Findings in Preparation for Clinical Trials.

Giuseppe Casalino1, Kamron N Khan2, Monica Armengol3, Genevieve Wright4, Nikolas Pontikos4, Michalis Georgiou4, Andrew R Webster4, Anthony G Robson4, Parampal S Grewal4, Michel Michaelides5.   

Abstract

PURPOSE: To investigate the clinical course, genetic findings, and phenotypic spectrum of autosomal recessive bestrophinopathy (ARB) in a large cohort of children and adults.
DESIGN: Retrospective case series. PARTICIPANTS: Patients with a detailed clinical phenotype consistent with ARB, biallelic likely disease-causing sequence variants in the BEST1 gene, or both identified at a single tertiary referral center.
METHODS: Review of case notes, retinal imaging (color fundus photography, fundus autofluorescence, OCT), electrophysiologic assessment, and molecular genetic testing. MAIN OUTCOME MEASURES: Visual acuity (VA), retinal imaging, and electrophysiologic changes over time.
RESULTS: Fifty-six eyes of 28 unrelated patients were included. Compound heterozygous variants were detected in most patients (19/27), with 6 alleles recurring in apparently unrelated individuals, the most common of which was c.422G→A, p.(Arg141His; n = 4 patients). Mean presenting VA was 0.52 ± 0.36 logarithm of the minimum angle of resolution (logMAR), and final VA was 0.81 ± 0.75 logMAR (P = 0.06). The mean rate of change in VA was 0.05 ± 0.13 logMAR/year. A significant change in VA was detected in patients with a follow-up of 5 years or more (n = 18) compared with patients with a follow-up of 5 years or less (n = 10; P = 0.001). Presence of subretinal fluid and vitelliform material were early findings in most patients, and this did not change substantially over time. A reduction in central retinal thickness was detected in most eyes (80.4%) over the course of follow-up. Many patients (10/26) showed evidence of generalized rod and cone system dysfunction. These patients were older (P < 0.001) and had worse VA (P = 0.02) than those with normal full-field electroretinography results.
CONCLUSIONS: Although patients with ARB are presumed to have no functioning bestrophin channels, significant phenotypic heterogeneity is evident. The clinical course is characterized by a progressive loss of vision with a slow rate of decline, providing a wide therapeutic window for anticipated future treatment strategies.
Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autosomal recessive bestrophinopathy; BEST1; Electrophysiology; Gene therapy; Genetics; Retinal imaging

Year:  2020        PMID: 33039401     DOI: 10.1016/j.ophtha.2020.10.006

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

1.  Clinical-genetic findings in a group of subjects with macular dystrophies due to mutations in rare inherited retinopathy genes.

Authors:  Juan C Zenteno; Rocio Arce-Gonzalez; Rodrigo Matsui; Antonio Lopez-Bolaños; Luis Montes; Alan Martinez-Aguilar; Oscar F Chacon-Camacho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-08-10       Impact factor: 3.535

Review 2.  Fundus Autofluorescence and Clinical Applications.

Authors:  Cameron Pole; Hossein Ameri
Journal:  J Ophthalmic Vis Res       Date:  2021-07-29

3.  Clinical Heterogeneity in Autosomal Recessive Bestrophinopathy with Biallelic Mutations in the BEST1 Gene.

Authors:  Karsten Hufendiek; Katerina Hufendiek; Herbert Jägle; Heidi Stöhr; Marius Book; Georg Spital; Günay Rustambayova; Carsten Framme; Bernhard H F Weber; Agnes B Renner; Ulrich Kellner
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

4.  The Role of Optical Coherence Tomography Angiography (OCTA) in Detecting Choroidal Neovascularization in Different Stages of Best Macular Dystrophy: A Case Series.

Authors:  Yaqoob Qaseem; Olga German; Maria Vittoria Cicinelli; Rukhsana G Mirza
Journal:  Medicina (Kaunas)       Date:  2021-02-27       Impact factor: 2.430

5.  First Pediatric Case of Autosomal Recessive Homozygotic Bestrophinopathy due to Homozygous Mutation c.187G>C p. in Two Brothers.

Authors:  Stefan Bittmann; Elisabeth Luchter; Gloria Villalon; Elena Moschuring-Alieva; Lara Bittmann; Anne Weissenstein
Journal:  J Clin Med Res       Date:  2022-04-12

6.  IMPG2-associated unilateral adult onset vitelliform macular dystrophy.

Authors:  Michalis Georgiou; Muhammad Z Chauhan; Michel Michaelides; Sami H Uwaydat
Journal:  Am J Ophthalmol Case Rep       Date:  2022-09-06

7.  Clinical Features and Genetic Findings of Autosomal Recessive Bestrophinopathy.

Authors:  Hae Rang Kim; Jinu Han; Yong Joon Kim; Hyun Goo Kang; Suk Ho Byeon; Sung Soo Kim; Christopher Seungkyu Lee
Journal:  Genes (Basel)       Date:  2022-07-04       Impact factor: 4.141

8.  Clinical and visual electrophysiological characteristics of vitelliform macular dystrophies in the first decade of life.

Authors:  Srikanta Kumar Padhy; Deepika C Parameswarappa; Komal Agarwal; Brijesh Takkar; Shashwat Behera; Bhavik Panchal; Muralidhar Ramappa; Tapas Ranjan Padhi; Subhadra Jalali
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

9.  Impaired Bestrophin Channel Activity in an iPSC-RPE Model of Best Vitelliform Macular Dystrophy (BVMD) from an Early Onset Patient Carrying the P77S Dominant Mutation.

Authors:  Arnau Navinés-Ferrer; Sheila Ruiz-Nogales; Rafael Navarro; Esther Pomares
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

10.  Disease expression caused by different variants in the BEST1 gene: genotype and phenotype findings in bestrophinopathies.

Authors:  Katarzyna Nowomiejska; Fadi Nasser; Katarina Stingl; Simone Schimpf-Linzenbold; Saskia Biskup; Agnieszka Brzozowska; Robert Rejdak; Susanne Kohl; Eberhart Zrenner
Journal:  Acta Ophthalmol       Date:  2021-07-29       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.